IL117112A0 - Solid active compound preparations - Google Patents

Solid active compound preparations

Info

Publication number
IL117112A0
IL117112A0 IL11711296A IL11711296A IL117112A0 IL 117112 A0 IL117112 A0 IL 117112A0 IL 11711296 A IL11711296 A IL 11711296A IL 11711296 A IL11711296 A IL 11711296A IL 117112 A0 IL117112 A0 IL 117112A0
Authority
IL
Israel
Prior art keywords
pct
active compound
weight
solid active
compound preparations
Prior art date
Application number
IL11711296A
Other languages
English (en)
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of IL117112A0 publication Critical patent/IL117112A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Cosmetics (AREA)
IL11711296A 1995-02-14 1996-02-12 Solid active compound preparations IL117112A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19504832A DE19504832A1 (de) 1995-02-14 1995-02-14 Feste Wirkstoff-Zubereitungen

Publications (1)

Publication Number Publication Date
IL117112A0 true IL117112A0 (en) 1996-06-18

Family

ID=7753890

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11711296A IL117112A0 (en) 1995-02-14 1996-02-12 Solid active compound preparations

Country Status (25)

Country Link
US (1) US5939099A (cs)
EP (1) EP0809488B1 (cs)
JP (1) JP4049810B2 (cs)
KR (1) KR19980702193A (cs)
CN (1) CN1177584C (cs)
AT (1) ATE220541T1 (cs)
AU (1) AU4786096A (cs)
BG (1) BG101781A (cs)
BR (1) BR9606957A (cs)
CA (1) CA2211033C (cs)
CZ (1) CZ239497A3 (cs)
DE (2) DE19504832A1 (cs)
DK (1) DK0809488T3 (cs)
ES (1) ES2180738T3 (cs)
FI (1) FI973320A7 (cs)
HU (1) HUP9702424A3 (cs)
IL (1) IL117112A0 (cs)
NO (1) NO973730D0 (cs)
NZ (1) NZ302243A (cs)
PL (1) PL321755A1 (cs)
PT (1) PT809488E (cs)
SK (1) SK104397A3 (cs)
TR (1) TR199700786T1 (cs)
WO (1) WO1996025151A1 (cs)
ZA (1) ZA961137B (cs)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19531277A1 (de) * 1995-08-25 1997-02-27 Basf Ag Verwendung von Lipiden als Hilfsmittel bei der Herstellung von festen Arzneiformen nach dem Schmelzextrusionsverfahren
DE19536387A1 (de) * 1995-09-29 1997-04-03 Basf Ag Verfahren zur Herstellung von vitaminhaltigen festen Zubereitungen
CA2214895C (en) * 1997-09-19 1999-04-20 Bernard Charles Sherman Improved pharmaceutical composition comprising fenofibrate
TW568788B (en) * 1998-10-12 2004-01-01 Chugai Pharmaceutical Co Ltd Polymer combining with phosphoric acid and preparation containing the same
JP3572213B2 (ja) * 1999-01-18 2004-09-29 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロース
US6733789B1 (en) 1999-01-21 2004-05-11 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
DE19916383A1 (de) * 1999-03-31 2000-10-05 Schering Ag Pharmazeutische Zusammensetzung mit einem Extrusionsstoff
JP2000327701A (ja) * 1999-05-18 2000-11-28 Shin Etsu Chem Co Ltd 低置換度ヒドロキシプロピルセルロース及び固形製剤
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
DE19934610A1 (de) * 1999-07-23 2001-01-25 Bayer Ag Schnellfreisetzende Extrudate und Verfahren zu ihrer Herstellung sowie daraus erhältliche Zubereitungen
HUP0202827A2 (en) 1999-08-24 2002-12-28 Siemens Ag Suction intake device for an internal combustion machine
DE60025837T2 (de) 1999-09-24 2006-11-02 Janssen Pharmaceutica N.V. Antivirale feste dispersionen
WO2001034119A2 (en) * 1999-11-12 2001-05-17 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
US20040185099A1 (en) * 2000-01-20 2004-09-23 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US20050175687A1 (en) * 2001-01-30 2005-08-11 Mcallister Stephen M. Pharmaceutical formulations
US7883721B2 (en) 2001-01-30 2011-02-08 Smithkline Beecham Limited Pharmaceutical formulation
US7842308B2 (en) 2001-01-30 2010-11-30 Smithkline Beecham Limited Pharmaceutical formulation
GB0102342D0 (en) 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
JP2004525109A (ja) * 2001-02-15 2004-08-19 キング・ファーマシューティカルズ・インコーポレイティッド 安定化された甲状腺ホルモン医薬組成物、及びその製法
US20030224047A1 (en) * 2001-02-15 2003-12-04 Franz G. Andrew Levothyroxine compositions and methods
US20030032675A1 (en) * 2001-02-15 2003-02-13 Franz G. Andrew Manufacture of thyroid hormone tablets having consistent active moiety amounts
MXPA03011784A (es) 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
MXPA03011935A (es) * 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
US20030198671A1 (en) * 2001-08-10 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique plasma AUC properties
US20030198667A1 (en) * 2001-08-10 2003-10-23 Franz Andrew G. Methods of producing dispersible pharmaceutical compositions
US20030180353A1 (en) * 2001-08-10 2003-09-25 Franz G. Andrew Stabilized pharmaceutical compositions
US20030190349A1 (en) * 2001-08-10 2003-10-09 Franz G. Andrew Methods of stabilizing pharmaceutical compositions
US20030198672A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique triidothyronine plasma AUC properties
US20030199587A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique Cmax properties
US20030199586A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Unique levothyroxine aqueous materials
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US20030203967A1 (en) * 2001-08-14 2003-10-30 Franz G. Andrew Levothyroxine compositions having unique Tmax properties
US20030195253A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
US20040043066A1 (en) * 2001-10-29 2004-03-04 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
US7491407B2 (en) * 2001-10-31 2009-02-17 North Carolina State University Fiber-based nano drug delivery systems (NDDS)
US20030118652A1 (en) * 2001-11-15 2003-06-26 John Kelly Methods and compositions for use of (S)-bisoprolol
US20030091633A1 (en) * 2001-11-15 2003-05-15 John Kelly Methods and compositions for use of (S)-bisoprolol
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
PL371416A1 (en) 2002-02-01 2005-06-13 Pfizer Products Inc. Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
EP1920766B1 (en) 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
KR20040011248A (ko) * 2002-07-30 2004-02-05 환인제약 주식회사 암로디핀의 고체분산체와 그 제조방법 및 그를 포함하는약학적 조성물
AU2003249474A1 (en) 2002-08-12 2004-02-25 Pfizer Products Inc. Pharmaceutical compositions of semi-ordered drugs and polymers
EP1556021B1 (en) 2002-10-24 2007-12-19 Immupharm A/S Pharmaceutical compositions comprising flavonoids and menthol
EP1961419B1 (en) 2002-12-20 2010-03-24 Pfizer Products Inc. Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor
WO2004069180A2 (en) * 2003-01-31 2004-08-19 Smithkline Beecham Corporation Solid dispersion compositions
TW200526274A (en) 2003-07-21 2005-08-16 Smithkline Beecham Plc Pharmaceutical formulations
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
EP1696887A1 (en) * 2003-11-14 2006-09-06 Pfizer Products Inc. Solid amorphous dispersions of an mtp inhibitor for treatment of obesity
BRPI0417492A (pt) * 2003-12-09 2007-05-29 Pfizer composições compreendendo um inibidor de protease de hiv
EA010369B1 (ru) 2004-02-04 2008-08-29 Пфайзер Продактс Инк. Замещенные хинолиновые соединения
PE20060003A1 (es) 2004-03-12 2006-03-01 Smithkline Beecham Plc Formulacion farmaceutica polimerica para moldear por inyeccion
EA010888B1 (ru) 2004-05-25 2008-12-30 Пфайзер Продактс, Инк. Тетраазабензо[е]азуленовые производные и их аналоги
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
EP1804772B1 (en) * 2004-08-12 2011-10-05 Reckitt Benckiser Healthcare (UK) Limited Granules comprising a non-steroidal anti-inflammatory drug and a sugar alcohol made by melt extrusion
MX2007006534A (es) 2004-12-17 2007-07-25 Devgen Nv Composiciones nematicidas.
EP2548894A1 (en) 2005-02-03 2013-01-23 Bend Research, Inc. Pharmaceutical compositions with enhanced performance
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
BRPI0608609A2 (pt) * 2005-05-10 2010-01-19 Novartis Ag processo de extrusço para preparaÇço de composiÇÕes com compostos terapÊuticos fracamente compressÍveis
CA2647801C (en) * 2006-03-24 2015-04-14 Auxilium Pharmaceuticals, Inc. Process for the preparation of a hot-melt extruded laminate
EP2010156B1 (en) 2006-03-24 2016-11-16 Auxilium International Holdings, Inc. Stabilized compositions containing alkaline labile drugs
CN101460149A (zh) * 2006-06-07 2009-06-17 巴斯夫欧洲公司 醋酸乙烯酯-磺酸盐共聚物作为微水溶性化合物的加溶剂的用途
US8343547B2 (en) * 2006-08-08 2013-01-01 Shin-Etsu Chemical Co., Ltd. Solid dosage form comprising solid dispersion
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
US20080187579A1 (en) * 2007-02-01 2008-08-07 Pavan Bhat Extended-release dosage form
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
KR20100057789A (ko) * 2007-07-06 2010-06-01 바스프 에스이 활성 성분 제형물을 안정화시키기 위한 단독중합체 및 공중합체의 용도
JP5489997B2 (ja) 2007-07-19 2014-05-14 シマベイ セラピューティクス， インコーポレーテッド 糖尿病および代謝疾患の治療のためのＲＵＰ３またはＧＰＲｌ１９受容体のアゴニストとしてのＮ−アザ環状置換ピロール、ピラゾール、イミダゾール、トリアゾールおよびテトラゾール誘導体
JP2011503048A (ja) 2007-11-08 2011-01-27 グラクソ グループ リミテッド 医薬製剤
WO2009085637A1 (en) * 2007-12-21 2009-07-09 Url Pharma, Inc. Amorphous metaxalone and amorphous dispersions thereof
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
TW201002705A (en) * 2008-03-31 2010-01-16 Metabolex Inc Oxymethylene aryl compounds and uses thereof
BRPI0912014A2 (pt) 2008-05-09 2019-03-06 Grünenthal GmbH processo para a preparação de uma formulação em pó intermediária e uma forma de dosagem sólida final sob uso de uma etapa de congelamento por atomização
WO2009150228A2 (en) * 2008-06-13 2009-12-17 Glaxo Group Limited Pharmaceutical formulations
MX2010014566A (es) * 2008-07-03 2011-02-15 Novartis Ag Proceso de granulacion de fundido.
US20110160222A1 (en) * 2008-11-26 2011-06-30 Metabolex, Inc. Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
WO2010067233A1 (en) 2008-12-08 2010-06-17 Pfizer Inc. 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
CN102573805A (zh) 2009-07-22 2012-07-11 格吕伦塔尔有限公司 热熔挤出的控制释放剂型
RU2015138422A (ru) 2009-07-22 2018-12-25 Грюненталь Гмбх Стабильная при окислении, прочная на излом лекарственная форма
WO2011041154A1 (en) * 2009-10-01 2011-04-07 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
CA2799708A1 (en) 2010-05-21 2011-11-24 Pfizer Inc. 2-phenyl benzoylamides
EP2585048B1 (en) 2010-06-23 2018-04-11 CymaBay Therapeutics, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
BR112013005234A2 (pt) 2010-09-02 2016-05-03 Gruenenthal Gmbh forma de dosagem resistente à violação compreendendo um polímero aniônico.
NZ607392A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising inorganic salt
CN103260609B (zh) 2010-12-23 2017-08-11 雅培股份有限两合公司 基于固体分散体的固体延缓制剂
EP2675434A1 (en) 2011-02-17 2013-12-25 F.Hoffmann-La Roche Ag A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion
EA027817B1 (ru) * 2011-03-21 2017-09-29 Бёрингер Ингельхайм Интернациональ Гмбх Лекарственная форма, содержащая твёрдую амброксолсодержащую композицию, и ее применение
RS56527B1 (sr) 2011-07-29 2018-02-28 Gruenenthal Gmbh Tableta za trenutno oslobađanje leka rezistentna na zloupotrebu
PE20141638A1 (es) 2011-07-29 2014-11-22 Gruenenthal Chemie Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
SG11201405477XA (en) 2012-04-06 2014-11-27 Pfizer Diacylglycerol acyltransferase 2 inhibitors
DK2838512T3 (en) 2012-04-18 2018-11-19 Gruenenthal Gmbh MANIPULATED AND DOSAGE DUMPED PHARMACEUTICAL DOSAGE FORM
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
DK2925880T3 (da) * 2012-11-27 2020-09-21 Dsm Ip Assets Bv Fremgangsmåde til fremstilling af adskilte faste ekstruderede partikler
AR096439A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido que contiene una o más partículas
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
WO2014196519A1 (ja) * 2013-06-03 2014-12-11 信越化学工業株式会社 加熱溶融押出用組成物及びこれを用いた加熱溶融押出成型物の製造方法
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
BR112016010942B1 (pt) * 2013-11-15 2020-11-24 Dsm Ip Assets B.V Formulaqao de compostos pouco soluveis por meio de extrusao por fusao a quente e processo de extrusao por fusao a quente para a produqao da mesma
AU2014356581C1 (en) 2013-11-26 2020-05-28 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
EP3119757B1 (en) 2014-03-17 2018-05-16 Pfizer Inc Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
MX2016014738A (es) 2014-05-12 2017-03-06 Gruenenthal Gmbh Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol.
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
JP2018517676A (ja) 2015-04-24 2018-07-05 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時放出および溶媒抽出に対する耐性を有する改変防止製剤
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
BR112018006720B1 (pt) * 2015-10-07 2023-05-02 Dsm Ip Assets B.V Extrusados multivitamínicos, alimento, ração, formulações para cuidado pessoal e/ou farmacológicas ou pré-misturas dos mesmos
EP3493807A1 (en) 2016-08-03 2019-06-12 CymaBay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
WO2018115130A1 (en) 2016-12-23 2018-06-28 Hermes Arzneimittel Gmbh Oral pharmaceutical composition with improved taste-masking properties
WO2018163066A1 (en) 2017-03-10 2018-09-13 Pfizer Inc. Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
BR112021003039A2 (pt) 2018-08-31 2021-05-18 Pfizer Inc. combinações para o tratamento de nash/nafld e doenças relacionadas
EP3956031A1 (en) 2019-04-19 2022-02-23 Pfizer Inc. Anti-proliferative agents for treating pah
US12611401B2 (en) 2019-05-20 2026-04-28 Pfizer Inc. Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
CA3144848C (en) 2019-06-28 2023-11-21 Pfizer Inc. 5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
JP2021134211A (ja) 2020-02-24 2021-09-13 ファイザー・インク Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
PE20231215A1 (es) 2020-06-09 2023-08-17 Pfizer Compuestos espiro como antagonistas del receptor de melanocortina 4 y usos de los mismos
AU2022403203B2 (en) 2021-12-01 2025-09-25 Pfizer Inc. 3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure
CA3241470A1 (en) 2021-12-06 2023-06-15 Pfizer Inc. Melanocortin 4 receptor antagonists and uses thereof
IL319486A (en) 2022-10-07 2025-05-01 Pfizer HSD17B13 Inhibitors and/or Retarders
US20240182468A1 (en) 2022-10-18 2024-06-06 Pfizer Inc. Compounds for the activation of ampk
WO2024084363A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Use of patatin-like phospholipase domain-containing protein 3 compounds
CN120129681A (zh) 2022-10-18 2025-06-10 辉瑞大药厂 含Patatin样磷脂酶结构域的蛋白3（PNPLA3）调节剂
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors
JP2025541231A (ja) 2022-12-16 2025-12-18 ファイザー・インク ３－フルオロ－４－ヒドロキシベンズアミド含有阻害剤および／または分解剤ならびにそれらの使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5879915A (ja) * 1981-11-09 1983-05-13 Nippon Soda Co Ltd 棒状薬剤の製造方法
DE3612211A1 (de) * 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
JPH0347124A (ja) * 1989-04-20 1991-02-28 Fujisawa Pharmaceut Co Ltd 経口吸収用製剤
EP0462062B1 (de) * 1990-06-13 1994-11-09 Ciba-Geigy Ag Verfahren zum Überprüfen des Gelierprozesses nach dem Giessen eines reaktiven Harzsystems in eine Produktionsform
DE4031881C2 (de) * 1990-10-08 1994-02-24 Sanol Arznei Schwarz Gmbh Lösungsmittelfreie, oral zu verabreichende pharmazeutische Zubereitung mit verzögerter Wirkstoffreisetzung und Verfahren zu deren Herstellung
DE4138513A1 (de) * 1991-11-23 1993-05-27 Basf Ag Feste pharmazeutische retardform
JPH05139974A (ja) * 1991-11-26 1993-06-08 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固体分散体の製造法
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine

Also Published As

Publication number Publication date
NO973730L (no) 1997-08-13
WO1996025151A1 (de) 1996-08-22
NO973730D0 (no) 1997-08-13
DE59609451D1 (de) 2002-08-22
CA2211033A1 (en) 1996-08-22
US5939099A (en) 1999-08-17
FI973320L (fi) 1997-10-13
BG101781A (bg) 1998-03-31
EP0809488A1 (de) 1997-12-03
FI973320A0 (fi) 1997-08-13
CZ239497A3 (cs) 1998-01-14
DK0809488T3 (da) 2002-09-02
ATE220541T1 (de) 2002-08-15
CN1174503A (zh) 1998-02-25
EP0809488B1 (de) 2002-07-17
KR19980702193A (ko) 1998-07-15
ES2180738T3 (es) 2003-02-16
SK104397A3 (en) 1998-04-08
HUP9702424A2 (hu) 1998-06-29
JPH10513477A (ja) 1998-12-22
DE19504832A1 (de) 1996-08-22
PT809488E (pt) 2002-11-29
PL321755A1 (en) 1997-12-22
CA2211033C (en) 2005-04-26
NZ302243A (en) 1999-01-28
CN1177584C (zh) 2004-12-01
BR9606957A (pt) 1997-10-28
JP4049810B2 (ja) 2008-02-20
FI973320A7 (fi) 1997-10-13
ZA961137B (en) 1997-09-16
AU4786096A (en) 1996-09-04
HUP9702424A3 (en) 2001-03-28
TR199700786T1 (xx) 1998-02-21

Similar Documents

Publication Publication Date Title
ZA961137B (en) Solid active compound preparations.
AU7576896A (en) Lipopolyamines as transfection agents and their pharmaceutical applications
IE894048L (en) New therapeutically active compound and a process for its¹preparation
CA2219698A1 (en) Sustained-release preparation
FR2677984B1 (fr) Derives d'imidazoline n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
AU6818196A (en) Substituted 2,4-imidazolidinedione compounds as pharmaceutical active ingredients
ATE121295T1 (de) Augentropfenarzneimittel.
DE69525649D1 (de) Lamotrigin haltiges arzneimittel
IL117808A (en) 1, 3-dihydro-1-(phenylalkenyl)- 2h-imidazol-2-one derivatives, their preparation and pharmaceutical compositions containing them
ATE201680T1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure- additions-salze
IL117806A (en) 1,3-dihydro-2H-imidazol-2-one derivatives their preparation and pharmaceutical compositions containing them
AU8522491A (en) Substituted imidazoles, their preparation and pharmaceutical compositions
EP1132383A4 (en) NEW AGAROFURAN DERIVATIVES, THEIR PRODUCTION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE AS MEDICINE
IT1228437B (it) "derivati di 2,3,4,5,6,7 esaidro 2,7-metano-1,5 benzossazonina (rispettivamente 1,4 benzossazonina), procedimento per la loro preparazione e prodotti medicinali che contengono questi composti.
TR199900013T2 (xx) Yeni bile�ikler.
IL117045A (en) Substituted N-(2,3-dihydro-1,4-dioxino Ú2,3-b¾pyridine-2-yl) alkanediamine derivatives their preparation and pharmaceutical compositions containing them
MX9602772A (es) Nueva forma galenica de derivados de 5-nitroimidazol que es efectiva para el tratamiento de parasitos e infecciones de todo el tracto gastrointestinal.
AU8490991A (en) Substituted 2 imidazolone derivatives, their preparation and pharmaceutical compositions
IT8622783A0 (it) Derivati imidazolici adattivita' terapeutica, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
IT8820927A0 (it) Composto ad attivita'antiinfiammatoria, procedimento per la sua preparazione e relative composizioni farmaceutiche.
IT8721158A0 (it) Composto ad attivita'antiinfiammatoria, procedimento per la sua preparazione e relative composizioni farmaceutiche.
FR2731221B1 (fr) Nouveaux derives de l'ethyl-1 dihydro-1, 2 oxo-2 methylamino-3 quinoxaline, leur utilisation a titre de medicament et les compositions pharmaceutiques les comprenant
FR2640625B2 (fr) Nouveaux composes optiquement actifs derives de l'indane, leur application comme medicaments et les compositions pharmaceutiques les renfermant
ITMI911298A1 (it) Composti ad attivita' anticolinesterasi, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
ITMI911335A1 (it) Composti ad attivita' anticolinesterasi, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono